-

Agilent Announces CrossLab Group Leadership Transition

Mark Doak to Retire May 1, Padraig McDonnell to lead Agilent CrossLab Group

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that Mark Doak, Agilent senior vice president and president of the Agilent CrossLab Group, has decided to retire on May 1, 2020. The company has named Padraig McDonnell, currently vice president and general manager, Chemistries and Supplies Division, to succeed him. Doak will continue as an active member of the executive staff until his retirement date, working with McDonnell to ensure a smooth transition.

Mark Doak has had a successful 42-year career in the analytical and scientific-instrument industry. He started his career with Beckman Instruments and later joined Hewlett-Packard (Agilent’s predecessor) in 1982. During his tenure with Agilent, he has held various senior-management positions across marketing, quality and services. Doak has led the Agilent CrossLab Group since 2014.

“Mark has been a key contributor to Agilent’s success for many years,” said Mike McMullen, Agilent president and CEO. “His leadership, knowledge and drive have helped make Agilent the industry leader it is today. I personally want to thank Mark for all that he has done to help lead our company and wish him all the best in his retirement.

“I’m also extremely pleased that Padraig McDonnell has accepted the role of leading our CrossLab Group upon Mark’s retirement. His history as a key member of Mark’s team, combined with his broad-based experience, track record of results and outstanding leadership skills, make Padraig the ideal person to take on this assignment. I have the utmost confidence he will continue to produce the same high level of success that Mark has achieved.”

McDonnell has been with Agilent for 22 years and has served in a variety of key sales and business-unit leadership positions. Prior to his current role leading the Chemistries and Supplies Division for the past three years, McDonnell was the vice president and general manager of Agilent’s Life Science and Applied Markets Group for Europe, the Middle East and India.

“While I was conflicted about retiring, Agilent and the Agilent CrossLab Group are in a solid position to continue their positive growth trajectories and the timing was right from an organizational perspective,” Doak said. “I look forward to working closely with Padraig in the coming months to help ensure a seamless transition.”

About Agilent Technologies

Agilent Technologies Inc. (NYSE: A) is a global leader in life sciences, diagnostics and applied chemical markets. Now in its 20th year as an independent company delivering insight and innovation toward improving the quality of life, Agilent instruments, software, services, solutions and people provide trusted answers to customers' most challenging questions. The company generated revenue of $5.16 billion in fiscal 2019 and employs 16,300 people worldwide. Information about Agilent is available at www.agilent.com. To receive the latest Agilent news, subscribe to the Agilent Newsroom.

Follow Agilent on LinkedIn, Twitter, and Facebook.

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

Agilent Technologies Inc.

NYSE:A
Details
Headquarters: Santa Clara, California, USA
CEO: Padraig McDonnell
Employees: 18000
Organization: PUB

Release Summary
Agilent announces CrossLab Group leadership transition; Mark Doak to retire May 1. Padraig McDonnell selected as his replacement.
Release Versions
$Cashtags
Hashtags

Contacts

INVESTOR CONTACT:
Ankur Dhingra
+1 408-345-8948
ankur_dhingra@agilent.com

MEDIA CONTACT:
Tom Beermann
+1 408-553-2914
tom.beermann@agilent.com

More News From Agilent Technologies Inc.

Agilent Receives FDA Approval for PD-L1 IHC 28-8 pharmDx in Esophageal Squamous Cell Carcinoma (ESCC), Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinoma

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced that it has received U.S. Food and Drug Administration (FDA) approval for the PD‑L1 IHC 28‑8 pharmDx assay as a companion diagnostic to identify patients with esophageal squamous cell carcinoma (ESCC), gastric, gastroesophageal junction (GEJ), and esophageal adenocarcinoma who may be eligible for treatment with OPDIVO® (nivolumab) or OPDIVO QVANTIG® (nivolumab and hyaluronidase‑nvhy), Bristol Myers Squibb’...

Agilent Expands Altura Portfolio with Inert Size Exclusion and PLRP-S Columns for Biotherapeutic Analysis

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the latest expansion of its Altura HPLC column portfolio with the introduction of Altura size exclusion chromatography (SEC) and Altura PLRP-S columns, designed to support critical analytical workflows in biopharmaceutical development and production.The new SEC and PLRP-S columns support critical analytical workflows across a range of biotherapeutic modalities, including peptides, proteins, oligonucleotides...

Agilent Launches AI-Driven Analysis Module for Agilent xCELLigence RTCA eSight

SANTA CLARA, Calif.--(BUSINESS WIRE)--Agilent Technologies Inc. (NYSE: A) today announced the launch of Agilent xCELLigence RTCA eSight AI, a new AI-powered software module that simplifies label-free imaging analysis by reducing manual cell segmentation steps and parameter tuning and supporting more consistent results. The software upgrade enhances the unique dual-readout capabilities of the Agilent xCELLigence RTCA eSight instrument with AI-driven cell imaging analysis, enabling researchers to...
Back to Newsroom